Lexicon Pharmaceuticals, Inc. (LXRX)

5.58
0.08 1.41
NASDAQ
Prev Close 5.66
Open 5.65
Day Low/High 5.53 / 5.83
52 Wk Low/High 4.26 / 13.97
Volume 645.52K
Exchange NASDAQ
Shares Outstanding 106.27B
Market Cap 625.94M
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Lexicon Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - LXRX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Lexicon Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - LXRX

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc.

LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, Jan. 30, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lexicon Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc.

Federman & Sherwood announces that on January 28, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of Texas against Lexicon Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Lexicon Pharmaceuticals, Inc. - LXRX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Lexicon Pharmaceuticals, Inc. - LXRX

NEW YORK, Jan. 22, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc.

Oversold Conditions For Lexicon Pharmaceuticals (LXRX)

Oversold Conditions For Lexicon Pharmaceuticals (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of February 15th Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week Of February 15th Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 15th expiration.

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting LXRX Put And Call Options For November 16th

Interesting LXRX Put And Call Options For November 16th

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the November 16th expiration.

First Week Of January 2019 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2019 expiration.

Lexicon Pharmaceuticals To Highlight Pipeline Progress At R&d Day On April 10, 2018

Lexicon Pharmaceuticals To Highlight Pipeline Progress At R&d Day On April 10, 2018

Company to Profile Key Assets Projected to Drive Long-Term Growth

First Week of May 18th Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week of May 18th Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the May 18th expiration.

Lexicon Pharmaceuticals Becomes Oversold (LXRX)

Lexicon Pharmaceuticals Becomes Oversold (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of LXRX February 2018 Options Trading

First Week of LXRX February 2018 Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the February 2018 expiration.

First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the July 2018 expiration.

Short Interest Declines 13.8% For LXRX

Short Interest Declines 13.8% For LXRX

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 2,150,673 share decrease in total short interest for Lexicon Pharmaceuticals, Inc. , to 13,435,509, a decrease of 13.80% since 10/13/2017.

First Week of LXRX December 15th Options Trading

First Week of LXRX December 15th Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.

LXRX: Insiders vs. Shorts

LXRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/31/2017 settlement date, and Lexicon Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 31.32 "days to cover" versus the median component at 6.19.

TheStreet Quant Rating: D- (Sell)